Eli Lilly Ansoff Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Unlock the Full Amsoff Matrix for Deeper Strategic Insight
This Eli Lilly Amsoff Matrix Analysis gives a clear view of Eli Lilly's growth options across market penetration, market development, product development, and diversification. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report instantly.
Market Penetration
Eli Lilly and Company's tirzepatide share push
Eli Lilly and Company used Mounjaro and Zepbound to win share in type 2 diabetes and obesity. Mounjaro generated about $11.5 billion in 2024 sales, and Zepbound added about $4.9 billion, giving Eli Lilly and Company two blockbuster brands in the same incretin class. That scale makes share defense tougher for rivals, because Eli Lilly and Company can push on both demand and access at once.
Self-pay pricing widened access fast
Eli Lilly and Company widened Zepbound access with a direct self-pay route at about $399 to $499 a month, depending on dose and package. In 2025, that lower-friction price point helped reach patients facing coverage gaps, since obesity drug uptake is still limited by payer rules and prior auth. The move converted demand into fills faster than rebate-heavy access models.
Verzenio defended oncology share at scale
In 2025, Verzenio remained Eli Lilly and Company's breast cancer anchor, after 2024 sales of about $5.3 billion. Its use in both metastatic and adjuvant settings spans two major treatment stages, which keeps prescriber habits sticky and repeat use high. That broad clinical reach helped Eli Lilly and Company defend share at scale in an established oncology market.
LillyDirect reduced prescription friction
LillyDirect cut steps between patient interest and first fill for Eli Lilly and Company, which matters in obesity and diabetes where prior authorizations and specialist wait times slow starts. In 2025, Eli Lilly and Company reported about $59.4 billion in revenue, and faster access can help convert that demand into scripts sooner.
In a category won by convenience and persistence, even small drops in friction can shift share. LillyDirect gives Eli Lilly and Company a tighter path from search to start, which can lift adoption for high-demand drugs like Zepbound and Mounjaro.
Manufacturing scale protected demand capture
Eli Lilly and Company used its 2024 revenue base of about $45.0 billion to keep lifting manufacturing output, which made supply capture part of market penetration, not just a plant issue. In incretins, reliable supply helps convert demand into actual share, especially while rivals are still building capacity. That scale lets Eli Lilly and Company keep investing in volume, fill rates, and launches at the same time.
Lilly's 2025 growth engine: Mounjaro, Zepbound, and Verzenio
Eli Lilly and Company pushed market penetration in 2025 by pairing Mounjaro, Zepbound, Verzenio, and LillyDirect with tighter access and faster starts. Revenue reached about $59.4 billion, with diabetes and obesity demand still driving share gains while supply expansion helped turn interest into fills.
| 2025 metric | Value |
|---|---|
| Revenue | $59.4B |
| Mounjaro 2024 sales | $11.5B |
| Zepbound 2024 sales | $4.9B |
| Verzenio 2024 sales | $5.3B |
What is included in the product
Detailed Word Document
Editable Excel File
Market Development
Global rollout of Mounjaro expanded geography
In 2025, Eli Lilly and Company kept rolling out Mounjaro beyond the U.S., pushing it into more diabetes markets and local payer systems. That matters because Mounjaro is one of Eli Lilly and Company's two main growth brands, so each new country adds a new formulary, reimbursement path, and doctor network. Market development here is just the U.S. launch playbook repeated country by country, with local access rules shaping speed and sales.
Zepbound opened obesity demand outside the U.S.
Eli Lilly and Company used Zepbound, alongside Mounjaro, to build a 2-product incretin platform for obesity launches outside the U.S. That fits a market development move because obesity affects over 1 billion people worldwide, while treatment use is still low in many developed markets. In Q1 2025, Eli Lilly and Company reported $12.73 billion in revenue, with Zepbound sales of $2.31 billion, showing how fast demand can scale.
Kisunla created a new Alzheimer's market entry
Eli Lilly and Company used Kisunla to enter the Alzheimer's disease market after the U.S. FDA approved it in 2024. In 2025, Alzheimer's affected about 7.2 million Americans age 65 and older, so this opened a large new specialist channel with amyloid PET or CSF testing, infusion-site logistics, and MRI monitoring. The market has different reimbursement and patient-selection rules than diabetes or oncology, even though it still depends on specialty care.
Regional access plans broadened ex-U.S. reach
Eli Lilly and Company is widening access in Europe, Asia-Pacific, and Latin America, so market development now means three separate regional plays, not one global rollout. Each market needs local pricing, tender bids, and supply coordination, because payers and regulators approve drugs country by country. That matters in pharma: a launch can stall if reimbursement talks or hospital tenders lag in even one major market.
Specialty channels extended into new care settings
Eli Lilly and Company is pairing launches with specialty pharmacy and digital support to reach patients beyond major academic centers. In 2025, this matters in obesity, diabetes, and neurology, where care is often split across primary care, telehealth, and local specialists, so access depends on distribution, not just demand.
That is market development in practice: a new geography is also a new access model. By broadening specialty channels, Eli Lilly and Company can move into fragmented care settings faster and keep patients on therapy longer.
Lilly's Global Expansion Is Powering 2025 Growth
Eli Lilly and Company's market development in 2025 is about pushing Mounjaro, Zepbound, and Kisunla into new countries and payer systems, where access rules decide speed. This is working: Q1 2025 revenue was $12.73 billion, with Zepbound at $2.31 billion. In pharma, each new market means new reimbursement, tenders, and specialty-channel setup.
| Metric | 2025 |
|---|---|
| Q1 revenue | $12.73B |
| Zepbound sales | $2.31B |
| Obesity prevalence | 1B+ people |
What You See Is What You Get
Eli Lilly Reference Sources
This Eli Lilly Amsoff Matrix Analysis preview is the same document you'll receive after purchase – no sample, no placeholders, just the real file. The full report includes the complete analysis in a clear, professional format. Buy now to unlock the exact version shown here.
Product Development
Orforglipron is the next oral incretin bet
Eli Lilly and Company is advancing orforglipron, a once-daily oral GLP-1 in late-stage development, as a clear product-development play. A pill could remove the injection barrier for millions, while keeping the same high-demand obesity and diabetes franchise. Lilly said it expects 2025 phase 3 data across obesity, diabetes, and sleep apnea, extending a business that generated $45.0 billion in 2024 revenue.
Retatrutide targets a wider metabolic profile
Eli Lilly and Company is advancing retatrutide as a next-gen obesity and cardiometabolic therapy that hits GLP-1, GIP, and glucagon receptors. In phase 2, the top dose cut body weight by 24.2% at 48 weeks, pointing to broader metabolic control than 1-target drugs.
That gives Eli Lilly and Company a strong follow-on path after tirzepatide, which posted $16.5B in 2024 sales and drove $45.0B total revenue.
Kisunla evidence is moving earlier in disease
Eli Lilly and Company is pushing Kisunla beyond late-stage Alzheimer's care into earlier disease evidence, which is the core product development move here. In the U.S., more than 7 million people live with Alzheimer's, and many are diagnosed after major decline, so earlier use could lift the addressable market fast. As a 2025 growth signal, this shift is about turning Kisunla from a launch product into a broader clinical platform.
Omvoh is building a 2-indication GI franchise
Omvoh is a classic product-development move: Eli Lilly and Company is extending one approved GI asset from ulcerative colitis into Crohn's disease, so the brand now spans 2 inflammatory bowel disease indications. That broadens the addressable market without building a new molecule from scratch. In 2025, the key value is life-cycle extension, higher use per patient, and more room for long-run revenue growth.
New delivery formats support persistence
Eli Lilly and Company is widening Zepbound access with self-pay vial formats at 2.5 mg and 5 mg, plus dose access improvements that lower the cash barrier at launch. In obesity care, where weekly injectables keep growing fast in 2025, easier packaging can cut pharmacy drop-off and support longer use. That makes delivery design part of the product, not an afterthought, because persistence supports both outcomes and repeat revenue.
Eli Lilly's Next-Gen Obesity Pipeline Targets Bigger Growth
Eli Lilly and Company is using product development to extend its obesity and metabolic franchise, led by orforglipron and retatrutide. Orforglipron is in late-stage trials, while retatrutide showed 24.2% weight loss at 48 weeks in phase 2. That sits on top of $45.0 billion 2024 revenue and $16.5 billion Zepbound sales.
| Asset | 2025 signal |
|---|---|
| orforglipron | Late-stage oral GLP-1 |
| retatrutide | 24.2% weight loss |
| Zepbound | $16.5B sales |
Diversification
POINT Biopharma added radiopharmaceutical exposure
Eli Lilly and Company bought POINT Biopharma for about $1.4 billion, a clear diversification move into radiopharmaceutical cancer therapy. The deal adds a new technology platform and a different oncology submarket, including PSMA-targeted and other radioligand programs, so Eli Lilly and Company is less tied to small molecules and antibodies alone. In Amsoff Matrix terms, this is diversification into a higher-risk, higher-optionality growth path.
Morphic expanded immunology beyond Lilly core assets
Lilly and Company agreed to buy Morphic for about $3.2 billion, adding oral integrin inhibitor assets. This widened Lilly and Company's reach in inflammatory disease with a different drug modality. It is diversification because the market, mechanism, and go-to-market playbook differ from Lilly and Company's 2025 incretin-led growth.
Kisunla diversified the portfolio into neuroscience
Eli Lilly and Company moved beyond diabetes with Kisunla, a 2024 Alzheimer's launch that slowed cognitive decline by 35% at 76 weeks in the TRAILBLAZER-ALZ 2 study. Neuroscience has tougher trial design, ARIA safety monitoring, and more complex payer review than metabolic care. That broadens Eli Lilly and Company across 2 big growth pools, not just one, and reduces reliance on diabetes alone.
Portfolio breadth now spans 5 therapeutic areas
Eli Lilly and Company now spans diabetes, obesity, oncology, immunology, neuroscience, and cardiovascular health. In 2025, that broader mix helped offset reliance on any one block, with Mounjaro and Zepbound still driving outsized growth while other programs added depth.
This 5-plus area spread lowers single-franchise risk, so a slowdown in one area does not automatically hit the whole model. It also gives Eli Lilly and Company more shots at sustained sales growth as new launches scale.
Adjacent science reduces single-platform risk
Eli Lilly and Company is spreading risk across GLP-1s, antibodies, oral small molecules, and radiopharmaceuticals, so one setback does not define the whole pipeline. That mix was broader in 2025 than 3 to 5 years ago, when the story leaned much more on a few drug classes. The benefit showed up in scale too, with 2025 revenue expected to stay above $50 billion as multiple platforms now feed growth.
Eli Lilly's 2025 diversification push broadens growth beyond incretins
Diversification is a key Eli Lilly and Company Ansoff move in 2025, with POINT Biopharma adding radioligand oncology and Morphic adding oral integrin therapy. These bets expand Eli Lilly and Company beyond incretins into new drug classes, markets, and payers, so growth is less tied to one franchise. With 2025 revenue above $50 billion, the wider mix now supports scale and lowers single-product risk.
| Move | 2025 role | Value |
|---|---|---|
| POINT Biopharma | Oncology diversification | $1.4B |
| Morphic | Immunology diversification | $3.2B |
| Eli Lilly and Company | 2025 revenue | >$50B |
Frequently Asked Questions
Eli Lilly and Company's penetration strategy is driven by tirzepatide scale, access, and supply execution. Mounjaro generated about $11.5 billion in 2024 sales and Zepbound about $4.9 billion, while LillyDirect and self-pay pricing around $399 to $499 per month reduce friction. That combination helps convert demand into share faster than promotion alone.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.